A coating technique for high-friability tablets using PHARMACOAT® [P-011]
When high-friability tablets are coated using aqueous coating systems with a water soluble polymer such as PHARMACOAT® (Hypromellose, HPMC), problems such as peeling and bridging frequently occur. In this study, a coating technique that ameliorates these problems was designed and verified using PHARMACOAT® to apply logos to highly friable tablets.
An advanced coating formulation with PVA and HPMC [P-012]
In this experiment the suitability of a PVA and HPMC mixture as a tablet coating solution was tested.
An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
Film coated tablets containing water sensitive API often use a coating solvent consisting of a high content of organic solvents such as ethanol in water. In this study, a method for solution preparation with Pharmacoat in mixed solvents of high ethanol content in water, and coating technique are introduced.
Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
The present study focuses on understanding the effect of formulations and process parameters on twin screw granulation by application of L-HPC as binder/disintegrand and PHARMACOAT® as granulation binder using Design of Experiment tools.
Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
Solid dispersion is a technique used to enhance the bioavailability of poorly-soluble drugs in increase their solubility. In this study, as solid dispersion preparation method using Pharmacoat as a carrier is introduced, along with its application to solid dosage forms.
Coating formulation for logo tablets [P-013]
In this study, using ibuprofen as a model drug, the logo tablets with 50% ibuprofen were prepared. Then several coating formulation were used to coat these tablets and the results were compared in order to solve the logo bridging problem.
Comparative study of wet granulation binders [P-017]
The use of granulation is getting more popular not only for pharmaceutical applications, but also for nutraceutical applications. In this study, several wet granulation binders which are commonly used for nutraceutical applications are evaluated.
Dissolution behavior of various HPMC lower viscosity grades [P-014]
Solution with PHARMACOAT® or low viscosity grade of methylcellulose (METOLOSE® SM-4) is easily prepared by dispersing the cellulosic powder in hot water and then cooling down the mixture, because these cellulosic powder cannot be dissolved in hot water. The dissolution behavior of these low viscosity grades are introduced in this study.
Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
The mechanical properties of coating films are important characteristics because they affect various properties of film-coated dosage forms.
Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
In this study, the effect of plasticizers, sugars and lower viscosity polymers on the mechanical properties of cast hypromellose films was investigated using various grades of Pharmacoat.
Film properties of HPMC and MC [G-002]
PHARMACOAT® is listed in the USP as Hypromellose (substituion type 2910). Film properties of several PHARMACOAT® products and other related low viscosity grade materials were investigated. The results are shown in this document.
Film properties of low-viscosity grade cellulose derivatives [G-011]
Basic information about Film Properties of Low-Viscosity Grade Cellulose Derivatives.
Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
To calculate the oxygen permeability coefficient an aqueous solution of PHARMACOAT® or METOLOSE® was spread onto a glass plate and dried afterwards. See the results of the experiment in this document.
Solubility of PHARMACOAT® 606 in acetone/water mixtures [P-016]
The solubility of PHARMACOAT® 606 (P-606) in the mixtures of acetone/water was investigated. The polymer concentration was 5%.
Solubility of PHARMACOAT® 606 in alcohol-water mixtures [P-004]
The solubility of Pharmacoat 606 in the mixture of methanol/water, ethanol/water and isopropyl alcohol (IPA)/water was investigated.
Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
Improving acceptability and palatability of medicines is an important task for formulators. A popular technique is taste masking of oral solid dosage forms by coating with suitable polymers.
METOLOSE®
Dissolution behavior of various lower viscosity grades [P-014]
Solution with PHARMACOAT® (hypromellose) or low viscosity grade of methylcellulose (METOLOSE® SM-4) is easily prepared by dispersing the cellulosic powder in hot water and then cooling down the mixture, because the cellulosic powder cannot be dissolved in hot water. The dissolution behavior of these low viscosity grades are introduced in this study.
Film properties of HPMC and MC [G-002]
PHARMACOAT® is listed in the USP as Hypromellose (substitution type 2910). Film properties of several PHARMACOAT® products and other related low viscosity grade materials were investigated. The results are shown in this document.
Film properties of low-viscosity grades cellulose derivatives [G-011]
Overview of different film properties of low-viscosity grades cellulose derivatives.
METOLOSE® SM-4 for pellet film coating [M-002]
Film coating sometimes is used to protect coated pellets or to prevent chemical interactions between active ingredients and excipients, however regular film coating agents such as PHARMACOAT® are difficult to use for pellet coating due to agglomeration during the fluid bed coating process. METOLOSE® SM-4, an extremely low viscosity methycellulose is useful for aqueous film coating of pellets since it is less sticky and water soluble.
Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
To calculate the oxygen permeability coefficient an aqueous solution of PHARMACOAT® and METOLOSE® was dried.
Solubility of HPMC and MC in organic solvents [M-004]
Hypromellose and Methycellulose is insoluble in organic solvents and in this study shows the solubility of HPMC and MC is different organic solvents.
Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
Taste masking is a common issue in formulation development. In this study, as aqueous coating using Metolose SM-4 and acrylic polymer was applied to taste masking.
METOLOSE® SR
A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
The robustness of the wet granulation process was investigated in preparing Metformin HCL extended release matrix tablets using Metolose 90SH 15000SR. To observe the relationship between the processing parameters and tablet performance, an orthogonal-array design was applied to the evaluation.
Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
The preparation of bilyaer tablets using L-HPC and Metolose SR was studied. The best grade of L-HPC was selected using preliminary study to reduce the anti lamination and then applied in a rotary tablet press.
Coating application of METOLOSE® in extended release pellet formulation [SR-020]
Carbamazepine is considered a first line drug in the treatment of epilepsy and specific analgesic for trigeminal neuralgia. It is currently coming in three forms: an oral extended release tablet, an oral extended release capsule and an oral liquid suspension. Hence the purpose of this development was to formulate carbamazepine extended release pellets by coating application using METOLOSE® 90SH-100SR as release controlling agent.
Coating application of METOLOSE® in sustained release tablets [SR-019]
Hydrophilic matrices system is among the most widely used technology for oral sustained release drug delivery systems, providing robust formulations and straight forward tablet production. For a high dose, high solubility drug, a high polymer concentration is often required to achieve sustained release. Get to know more in this document.
Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
In this study, using theophylline as a model drug, dissolution profiles of matrix tablet which were prepared with same formulation by the different methods were compared.
Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
The purpose of this study was to compare direct compression and wet granulation for preparation of hydrophilic matrix tablets using Metolose SR. Tablet productivity using a s rotary tablet press was investigated, specifically for tablet weight deviation.
Formulation of metformin HCl sustained release tablets [SR-018]
The purpose of this study was to formulate a metformin hydrochloride (HCl) sustained release (SR) tablets 1000 mg with least tablet weight.
Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
The porpuse of this study was to formulate a paracetamol sustained release (SR) tablets 650 mg which will comply with the USP dissolution specification, keeping all other tablet parameters at desired level.
Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
The impact of METOLOSE®SR grades combinations on drug release in carbamazepine extended release matrix tablet formulation was investigated.
METOLOSE® SR in 500 mg HCl extended release tablets: simulation of high speed compaction [SR-016]
In this study, we demonstrated the application of high viscous hypromellose METOLOSE® SR in a high speed tablet compression simulation of metformin HCl sustained release tablets.
Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
In this document, the relationship between HELOS & RODOS (by Fraunhofer) and Malvern's Mastersizer 3000 (by Mie and Fraunhofer) is introduced.
QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
In this study, the effects of METOLOSE® SR properties on in vitro drug release were investigated using QbD principles.
QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
In this study, the effects of METOLOSE® SR properties on in vitro drug release were investigated using QbD principles
QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
In this study, the effects of METOLOSE® SR properties on in vitro drug release were investigated using QbD principles.
Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
An aqueous alcoholic solution is one of the suitable solvents to prepare hydrophilic matrix tablets by wet granulation. In this study, the effect of ethanol-water ratio and granulation time was examined.
The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
In this study, the effect of adding anionic polymer, Sodium Carboxymethylcellulose (CMCNa), was investigated. The different APIs with different solubilities were evaluated using various hypromellose dosages.
The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
In this study, theophylline which has poor flowability was selected as a drug model, a glidant (colloidal silicon dioxide) was added to the formulation containing METOLOSE® SR. The powder flowability was evaluated in order to see the effect of glidant.
The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
In this study, the influence of the solubility of the API on its dissolution profile was investigated. Three APIs with different solubility levels and formulated using various levels of hypromellose were evaluated.
HPMCP
Application of HPMCP and SmartEX® in the development of MUPS-ODT for Lansoprazol 15 mg [H-020, SE-007]
Tablets prepared by compaction of modified release/enteric coated or uncoated pellets are called as multiple unit particulate/pellet system (MUPS). Find out more in this document.
Application of HPMCP in extended release matrix tablet formulation [H-023]
The purpose of this study was to formulate extended release matrix tablets using HPMCP as pH dependent polymer with the focus on granulation solvent, stage of addition of HPMCP and HPMCP concentration.
Application of HPMCP in the development of rabeprazole sodium delayed release tablet by organic enteric coating [H-022]
The purpose of this development is to formulate an organic enteric coating system for the development of rabeprazole sodium delayed release (DR) tablets strength 20 mg as per Indian Pharacopoeia (IP).
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
In this study dissolution behavior of fine particles coated with aqueous (A-044) and organic solvent system (H-012) were evaluated. Different enteric/water-soluble polymer ratio and coating amount had also been studied.
Enteric coating of hard gelatin capsules using HPMCP [H-006]
The technical sheet gives an example of enteric coating of hard gelatin capsules using HPMCP.
Enteric coating of soft gelatin capsules with HPMCP [H-018]
Enteric coating of soft gelatin capsules is one of the tedious processes to perform. This type of coating generally is recommended mostly in vitamin capsules. Hence, the purpose of this development is to formulate an enteric coating system for soft gelatin capsules with Hypromellose Phthalate (HPMCP) in pan coater.
Film solubility of mixed HPMCP [H-011]
In this study, the relationship between the mixing ratio of HP-50 and HP-55 and the film solubility was investigated.
HPMCP - typical coating conditions for tablets (1) [H-002]
Examples of formulations using HPMCP in different solvent systems and their typical coating conditions for a batch size of 5kg.
HPMCP - typical coating conditions for tablets (2) [H-003]
Examples of formulations using HPMCP in different solvent systems and their typical coating conditions for a batch size of 1.5kg.
HPMCP - typical coating conditions for tablets [H-001]
Examples of formulations using HPMCP in different solvent systems and their typical coating conditions for a batch size of 5kg.
Hydrolysis of HPMCP in ethanol-water solution [H-005]
Stability of the ethanol-water coating solution of Hypromellose Phthalate (HP-55 & HP-50) was studied.
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
The IR spectrums of all the grades of HPMCP and Shin-Etsu AQOAT® are presented
Itraconazole 65 mg capsule using HPMPC-50 by solid dispersion approach [H-021]
The purpose of this development was to formulate Itraconazole solid dispersion using hypromellose phthalate HP-50 as a carrier polymer by different process techniques.
Neutralization effect on Hypromellose Phthalate (HPMCP) using different alkalizers in enteric coating [H-024]
Residual solvent in ethanol/water HPMPC-55 tablet coating [H-007]
The ethanol/water system is commonly used for HPMCP tablet coating. Ethanol is categorized as a class 3 solvent in the ICH guidelines and its regulated upper limit is 5,000ppm. The effect of operating condition on the level of residual ethanol has been studied.
Solubility of HPMCP in mixed organic solvents [H-010]
In this study, solubility of HPMCP in mixed organic solvents are discussed.
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Preparation methods of organic solution of HPMCP and Shin-Etsu AQOAT® are described as follows. The solvent composition is ethanol/water (80/20) and the polymer concentration is 8% which is the standard concentration as a coating solution.
Stability of HPMCP coated tablets [H-015]
HPMCP coated tablets using basic lactose-cornstarch as placebo were subjected to accelerated stability tests.
Stability of HPMCP under humid storage conditions [H-016]
Stability of Hypromellose Phthalate (HP-55, 55S and 50) under humid storage conditions was studied.
Shin-Etsu AQOAT®
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
3D printing (3DP) appears as a new chapter of opportunities for the pharmaceutical research. It brings the possibility to personalize medicines according to the individual patient information, in order to have an optimal dose.
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
In this study, a solid dispersion preparation method using Shin-Etsu AQOAT® (HPMCAS) as a carrier is introduced, along with its application to solid dosage forms.
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
The purpose of this development was to formulate ranolazine extended release matrix tablets using pH dependent polymer (Shin-Etsu AQOAT®, HPMCAS) which control and inhibit rapid drug release in stomach.
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
In this study, an amino acid, L-arginine was used to partially neutralize HPMCAS, which provided a stable dispersion in combination with the plasticizer.
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Coating parameters of a tablet batch size 5-100kg
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Preparation of coating dispersion
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Using a small tabletop coating machine we coated tablet batch size of 300g
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
In this study, aqueous enteric coating for lansoporazole pellets using Shin-Etsu AQOAT® was studied. The result of the comparative study with another enteric coating excipient, methacylic acid-ethyl acrylate copolymer, was also introduced.
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
We have applied an aqueous enteric coating to the soft gelatin capsules, and their operating parameters and key points are shown in this report.
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
The purpose of this study is to formulate an aqueous enteric coating system for soft gelatin capsules using Shin-Etsu AQOAT® by two different techniques i.e. partially neutraliziation technique using l-arginine and aqueous coating using triacetin as a plasticizer.
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
In this study, a new aqueous coating formulation based on partial neutralization with amino-acid for mini-tablets with diameter of 3 mm has been introduced.
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
The preparation of neutralized solutions, behavior of bound ammonia and the properties of cast films are discussed in the following pages.
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Examples of granule coating and tablet coating are presented in this part. Take a look at Part 1 as well.
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Coated granules and tablets referred to Part 2 of this technical information were subjected to storage-stability tests (See Part 1).
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): L-arginine partly neutralized [A-065]
This study describes the systematic investigation of L-arginine partly neutralized coating formulations for AS-LF, AS-MF and AS-HF grades.
Aqueous fine particle coating with angled spray [A-044]
Aqueous fine particle coating using a newly developed fluidized bed coating system equipped with side mounted angled spray gun is introduced in this report.
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
In this study, we introduce an optimized formulation with improved heat coagulation stability and process conditions for coating equipment from three different manufacturers.
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
In this study, different coating methods were applied on riboflavin pellets and the results were compared.
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
This study compares the enteric coating of mini-tablets using Shin-Etsu AQOAT® (HPMCAS) in perforated pan and fluid bed wurster typ processes.
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
In this study, the relationship between concentration and viscosity in several organic solvents are introduced.
Direct compression of spray dried dispersion [A-072]
In this study, the SDD was prepared with Shin-Etsu AQOAT® (HPMCAS) as a carrier and mixed other additives with excellent flowability.
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dissolution behavior of fine particles coated with aqueous and organic solvent system were evaluated.
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
The objective of this study was to assess the effect of hot melt extrusion (HME) on the physiochemical properties of HPMCAS
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
In this study, the effect of substitution levels of HPMCAS on polymer characteristics such as Tg (the glass transition temperature) and on the drug dissolution profile of Nifedipine by capillary rheometer was investigated.
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
The following data shows an example of enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS).
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
This study describes enteric coating of omeprazole granules using Shin-Etsu AQOAT® without a plasticizer.
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
HPMCAS can be used for solvent based coating. One of the advantages is using ethanol-water mixtures greater amount of water can be added to the formulation compared to an HPMCP.
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Coating parameters granules batch size 1.5kg
Impact of process parameters to solid dispersion particles [A-071]
In this study, ASD with Nifedipine (NIF) and Shin-Etsu AQOAT® (HPMCAS) was prepared by SD with various process parameters and the influence to the particle shape was studied.
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
To simulate the influence of alcoholic beverages, the gastric resistance of tablets coated with hypromellose acetate succinate (HPMCAS) was tested in a test fluid containing ethanol.
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
The IR spectrums of all the grades of HPMCP and Shin-Etsu AQOAT® are presented
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
In this study we investigated the mechanical properties of ASD filaments and milled extrudates prepared by HME using Shin-Etsu AQOAT® and either itraconazole or fenofibrate.
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
We present the preparation and downstream processing of an amorphous solid dispersion with itraconzole (ITZ) and Shin-Etsu AQOAT® using HME and differnt milling technologies. Tablets were prepared from milled extrudates and analyzed.
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Enteric coating agents are commonly used as aqueous dispersions for aqueous coating process as they are insoluble in purified water. Take a look at Part 1 as well.
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
It is important to know minimum film Formation temperature of polymers for characterization of the coating formulations. We investigated minimum film Formation temperature of Shin-Etsu Aqoat (HPMCAS).
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Please find the method and results of the molecular weight of Shin-Etsu Aqoat.
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
In this study, we demonstrate the preparation of a nifedipine (solubility of 0,0056 mg/ml) solid dispersion and subsequent downstream processing, including automated cutting of the extrudates into well-defined pellets.
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Various kinds of coating techniques can be applied using Shin-Etsu AQOAT® (HPMCAS). Get to know more in this document.
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
This study describes the scale-up of the partially ammonia neutralized coating dispersion from lab to production scale.
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solid dispersions of Nifedipine (DP) using HPMCAS were prepared by hot-melt extrusion (HME) and evaluated.
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Typical alkali solutions such as sodium bicarbonate and sodium hydroxide were studied to select cleaning media to use after a coating operation with Shin-Etsu AQOAT® (HPMCAS).
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
In this study, solubility of Shin-Etsu AQOAT® in mixed organic solvents are discussed.
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Preparation methods of organic solution of HPMCP and Shin-Etsu AQOAT® are described in this technical information.
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
In this study, the stability was tested at 150 - 180 °C for 15 - 30 minutes.
Taste masking coating for quinine tablets [A-061]
Tablets containing Quinine which is famous for the bitter taste were prepared for taste making trial. For taste masking, the tablet was coated with the mixture of Shin-Etsu AQOAT® and PHARMACOAT®.
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Improving acceptability and palatability of medicines is an important task for formulators. A popular technique is taste making of oral solid dosage forms by coating with suitable polymers. Get to know more in this technical information.
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
To improve heat sensitivity, triacetin (TA) was employed as an alternative plasticizer instead of TEC for aqueous coating dispersions. The triacetin formulation gives better handling performance at room temperature.
L-HPC
Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
This study focuses on understanding the effect of formulation and process parameters on twin screw granulation by application of L-HPC as binder/disintegrant and PHARMACOAT® as granulation binder using Design of Experiment (DoE) tools.
Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
The preparation of bilayer tablets using L-HPC and METOLOSE® SR was studied. The best grade of L-HPC was selected from the single-punch preliminary study and applied to the rotary tableting process.
Change of swelling performance of disintegrants after wet granulation [L-031]
In this study, swelling performance of disintegrants including L-HPC were analyzed. In order to see the difference between before and after wet granulation process, swelling performance of before and after wet granulation were compared.
Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
In this study, the formulations of paracetamol 500 mg tablets were compared using various L-HPC grades which have different hydroxypropyl content.
Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
In this study, the fomulations of paracetamol 500 mg tablets were compared using various L-HPC which has different particle attributes.
Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
In this study, the formulations of paracetamol 500 mg tablets were compared using various L-HPC which has different particle attributes.
Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
In this study, the formulations of paracetamol 500 mg tablets were compared using various L-HPC.
Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
There are 2 ways of incorporating L-HPC in the wet granulation process: internal addition and external addition. In this study, the effect of these 2 methods of incorporation on tablet properties was investigated.
Effect of L-HPC in the Drug Layering application [L-042]
Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
In this study, the effect of the added water quantity to the tablet properties at wet granulation process with L-HPC was investigated.
Influence of tablet shape on capping tendency [L-032]
In this study, influence of tablet shape and weight on capping was studied using a model formulation of glucosamine.
Interaction with L-HPC and vitamins [L-038]
In this study tablets with L-hPC and various vitamins were prepared and the interaction was compared to cros providone (cPVP) which is used for the same purpose to L-HPC.
Minitablets using L-HPC [L-024]
L-HPC is normally used as a binder and disintegrant for tablets and granules. In this study, L-HPC is used in a high API load minitablet formulation.
Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
The aim of this study is to address the design of ODTs using NBD grades of L-HPC.
Pellet extrusion - spheronizazion using L-HPC [L-011]
In this study, the performance of various grades of L-HPC was evaluated in the pellet extrusion and spheronization process.
Pellets preparation by drug layering using L-HPC [L-015]
L-HPC is a disintegrant which is often used for tablets and granules in order to improve disintegration and dissolution of the drug. In this document, pellets preparation by the drug layering technique using L-HPC is introduced.
Rapid release from hard capsules using L-HPC as a filler [L-009]
The release of a drug that is filled in hard capsules tends to be delayed because the materials in the capsule are clogged; this delay is espacially significant for herbal medicines. However, if L-HPC is used together with a drug as filler, clogging can be prevented because L-HPC absorbs water and disintegrates in a shorter time, which results in the rapid release of the drug.
Roller compaction using L-HPC - influence of re-processing [L-010]
In this study influence of repeated recycling process to the properties of granules and tablets were evaluated using L-HPC and MCC (microcrystalline cellulose).
Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
As L-HPC has good binding ability along with disintegration properties, its application in twin screw granulation needs to be understood. Along with this, the synergistic effect of L-HPC and PHARMACOAT® 603 in twin screw granulation has also been explored in the present study.
Super-high speed direct compression using L-HPC NBD [L-027]
In this study, tablet containing L-HPC NBD is prepared by super-high speed direct compression, and the deviation of the tablet properties is evaluated.
The effect of a glidant on L-HPC [L-029]
In this study, the effect of the glidant (colloidal silicon dioxide, Adsolider® 101) was verified using several L-HPC grades. Additionally tablet properties from placebo formulation which contained high level of L-HPC (40%) were also tested.
The effect of a glidant on L-HPC for dry granulation [L-030]
In this study, ethendiamide was used as a model drug, the effect of the glidant (colloidal silicon dioxide, Adsolider® 101) in dry granulation with L-HPC was studied.
Twin screw granulation using L-HPC [L-028]
In this study, the performance of L-HPC in twin screw granulation is discussed and basic process parameters are established.
Water absorption of L-HPC [L-041]
L-HPC absorbs water and significantly expands the volume. This swelling action results in tablets disintegrating quickly. In this study, water absorption of L-HPC was evaluated by wettability analysis.
Water binding capability of L-HPC in wet granulation [L-018]
In this study, the water binding capability of different grades of L-HPC in the wet granulation process was discussed and compared with the combination of microcrystalline cellulose and other disintegrant.
TYLOPUR®
Development of hydroxypropyl methylcellulose (HPMC) based titanium dioxide (TiO2) free coating (T-004)
TYLOPUR ClearCoat Nutra®
Application of TYLOPUR ClearCoat Nutra® 5 in Granulation and Tablet Coating
A Case Study of Glucosamine HCl
Tablet Coating with TYLOPUR ClearCoat Nutra® 5
Basic Process Parameters
TYLOPUR Xtend Nutra®
Extended Release of Vitamin C Matrix Tablets with TYLOPUR Xtend Nutra®
Extended-release tablets of Ashwagandha extract (KSM-66®) and L-theanine using TYLOPUR Xtend Nutra®
Melatonin Extended Release Formulation Development using TYLOPUR Xtend Nutra®
Applications
Cellulose ethers are used in a world of applications. Navigate the world with all the expertise of SE Tylose.
